Three-Year Longitudinal Analysis of Splicing Changes in Myotonic Dystrophy Type 1
Legare, C.; Planco, L.; Merritt, R.; Ripollone, J.; Conner, S.; Desrochers, L.; Nigim, F.; Roussel, M.-P.; Gagnon, C.; Cleary, J. D.; Berglund, A.; Duchesne, E.
Show abstract
Myotonic dystrophy type 1 (DM1) is caused by a CTG expansion in the 3' untranslated region of the DMPK gene that results in the expression of expanded CUG RNA which trap splicing factors resulting in widespread alternative splicing dysregulation. A panel of these splicing events, or splicing index (SI), is currently used to measure splicing dysregulation in DM1 patients. Despite significant interest in splicing, little is known about its progression over time in DM1. The objective of this study was to evaluate the changes in SI over 3 years in a well-phenotyped cohort of DM1 participants and identify factors contributing to these changes. RNA was extracted from vastus lateralis (VL) biopsies of 20 DM1 participants taken 3 years apart and the SI score was measured using targeted RNA sequencing. Baseline SI scores correlated with percent predicted muscle strength of the ankle dorsiflexors, knee extensors and hand grip. On average, SI scores worsened over 3 years, but the progression varied markedly among participants. Adult/juvenile phenotypes and lower baseline SI scores were among the factors associated with higher progression of SI scores over time. These findings emphasize the importance of integrating clinical phenotype and baseline molecular severity when interpreting longitudinal SI change, particularly in the context of clinical trials.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Creatine/creatinine ratio and myostatin as biomarkers to monitor muscle function in Duchenne Muscular Dystrophy patients 94%
- Duchenne muscular dystrophy patients lacking the dystrophin isoforms Dp140 and Dp71 and mouse models lacking Dp140 have a more severe motor phenotype 93%
- Cholesterol metabolism is a potential therapeutic target in Duchenne Muscular Dystrophy 93%
Similar papers in this journal
- Antisense oligonucleotide allele-specific targeting of EFEMP1 in a patient-derived model of Doyne honeycomb retinal dystrophy 90%
- Base editing strategy allows insertion of the A673T mutation in APP gene to prevent the development of Alzheimer's disease 89%
- Improving angiogenesis ameliorates the efficacy of ASO-based exon-skipping for the treatment of Duchenne muscular dystrophy 89%
Similar papers in this journal
- Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial 93%
- High-resolution mass spectrometry-based non-targeted metabolomic discovery of disease and glucocorticoid biomarkers in an animal model of muscular dystrophy 92%
- Effects of fibroblast growth factor 2 on muscle precursor cells from mouse limb and extraocular muscle 91%
Similar papers in this journal
Similar papers in this journal
- Splicing impact of deep exonic missense variants in CAPN3 explored systematically by minigene functional assay 92%
- Using single molecule Molecular Inversion Probes as a cost-effective, high-throughput sequencing approach to target all genes and loci associated with macular diseases 91%
- RNA sequencing identifies a cryptic exon caused by a deep intronic variant in NDUFB10 resulting in isolated Complex I deficiency. 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.